Table 2.

Current clinical trials targeting senescence against cancers

Category	Drug	Mechanism	Combination therapy	Condition	Design	Reference	Status
Regulation of senescence	Dexamethasone	Induction of senescence	Anti-PD-1 therapy	NSCLC	Phase I/II	NCT04037462	Terminated
	Rapamycin	Inhibition of SASP	Alisertib	Advanced Solid Tumors	Phase I	292	With result
Clearance of senescence	D plus Q	1st-generation senolytics	None	Childhood Cancer	Phase II	NCT04733534	Recruiting
			Anti-PD-1 therapy	Head and Neck Cancer	Phase II	NCT05724329	Active
			None	Triple-negative Breast Cancer	Phase II	NCT06355037	Recruiting
	Fisetin	1st-generation senolytics	None	Childhood Cancer	Phase II	NCT04733534	Recruiting
			None	Breast Cancer	Phase II	NCT05595499	Recruiting
			None	Breast Cancer	Phase II	NCT06113016	Recruiting
	ABT-263 (Navitoclax)	1st-generation senolytics	Gemcitabine	Advanced solid tumors	Phase I	293	With result
			Docetaxel	Advanced solid tumors	Phase I	294	With result
			None	Lymphoid malignancies	Phase IIa	295	With result
			Rituximab	Chronic lymphocytic leukemia	Phase II	296	With result
	ABT-737	1st-generation senolytics	None	Ovarian Cancer	Observational study	NCT01440504	Completed
	“One-two” punch therapy	Induction of senescence plus senolytics	Decitabine plus navitoclax	Acute myeloid leukemia	Phase Ib	NCT05222984	Active
			Olaparib plus navitoclax	Triple-negative Breast Cancer	Phase I	NCT05358639	Active

NSCLC, non-small-cell lung cancer; D, dasatinib; Q, quercetin; SCLC, small-cell lung cancer.